한국컴퓨터정보학회논문지 (Journal of the Korea Society of Computer and Information)

  • 제25권11호
  • /
  • Pages.179-185
  • /
  • 2020
  • /
  • 1598-849X(pISSN)
  • /
  • 2383-9945(eISSN)
한국컴퓨터정보학회 (Korean Society of Computer Information)
권호 표지
DOI QR코드

DOI QR Code

Impact Factors and Validity of Blood Variables on Death in COVID-19 patient: Using Data of Korea Disease Control and Prevention Agency

  • Kim, Yu-Rin (Dept. of Dental Hygiene, Sila University) ;
  • Nam, Seoul-Hee (Dept. of Dental Hygiene, Kangwon National University) ;
  • Kim, Seon-Rye (Dept. of Pharmacy, Kangwon National University)
  • 투고 : 2020.11.19
  • 심사 : 2020.11.27
  • 발행 : 2020.11.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

본 연구에서 우리는 COVID-19의 사망에 대한 영향요인과 혈액변수의 타당도를 제안하였다. 이 연구를 위하여 질병관리본부 중앙방역대책본부에서 제공하는 2020년 4월 30일까지 격리해제되었거나 사망한 COVID-19확진자 5628명의 임상역학정보를 활용하였으며, 자료는 R 3.4.1을 사용하여 분석하였다. 분석결과, 사망에 대한 위험요인으로 치매(HR 7.03), 많은 나이(HR 5.39), 높은 림프구(HR 4.66), 암(HR 4.27), 호흡곤란(HR 3.25), 만성폐쇄성 폐질환(HR 3.22), 의식변화(HR 3.13), 심장질환(HR 2.24), 높은 혈소판(HR 2.14), 비정상 이완기 혈압(HR 2.02), 열(HR 1.69)이 확인되었다. 사망에 대한 혈액검사의 타당도는 림프구, 헤모글로빈, 헤마토크리트, 혈소판, 백혈구 순으로 정확도가 높았다. 그러므로 COVID-19 환자를 치료할 때 사망의 위험요인으로 확인된 초기 임상적 특징 및 기저질환, 혈액검사의 소견을 고려하여 보다 효율적인 관리가 가능하도록 해야 할 것이다.

In this paper, we propose impact factors and validity of blood variables on death of COVID-19 patients. The clinical-epidemiological data of 5628 COVID-19 patients, provided from Korea Disease Control and Prevention Agency as day of 30th April 2020, were used. As results, impact factors of death were dementia, older age, high lymphocyte, cancer, dyspnea, COPD, change of consciousness, heart disease, high platelets, abnormal diastolic pressure and fever. The validities of blood variables for death were high in the order of lymphocyte, hemoglobin, hematocrit, platelet and WBC. Therefore, risk factors such as initial clinical characteristics, underlying disease and blood test results, could be regarded for efficient management of COVID-19 patients.

키워드

참고문헌

  1. C. Viboud, R. F. Grais, B. A. Lafont, M. A. Miller and L. Simonsen. "Multinational Influenza Sasonal Mortality Study Group. Multinational impact of the 1968 Hong Kong influenza pandemic: evidence for a smoldering pandemic", Journal of Infectious Disease, Vol. 192, No. 2, pp.233-48. Jun 2005. DOI: 10.1086/431150
  2. L. Simonsen, M. J. Clarke, L. B. Schonberger, N. H. Arden and N. J. Cox. "Pandemic versus epidemic influenza mortality: a pattern of changing age distribution", Journal of Infectious Disease, Vol. 178, No. 1, pp. 53-60. Jul. 1998 DOI: 10.1086/515616.
  3. S. Rewar, D. Mirdha and P. Rewar. "Treatment and prevention of pandemic H1N1 Influenza". Annual Global Health, Vol. 81, No. 5, pp. 645-53. September 2015 DOI: 10.1016/j.aogh.2015.08.014
  4. Korean Ministry of Health and Welfare. 2020. http://ncov.mohw.go.kr/
  5. Coronaboard. 2020. https://coronaboard.kr/
  6. World Coronaboard. 2020. retrieved from https://covid19.apthowmuch.com/
  7. A. E. Gorbalenya, S. C. Baker and R. S. Baric. "The species Severe acute respiratory syndromerelated coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2" Nature Microbiology, Vol. 5, No. 4, pp. 536-544. March 2020 Doi: 10.1038/s41564-020-0695-z.
  8. A. Giacomelli, L. Pezzati and F. Conti. "Self-reported olfactory and taste disorders in SARSCoV-2 patients: a cross-sectional study", Clinical Infectious Diseases, Vol. 71, No. 15, pp.ciaa330, March 2020 Doi: 10.1093/cid/ciaa330
  9. S. H. Lee and J. M. Kim. "Coronavirus Disease 2019 (COVID-19) Pandemic and the Challenge of Public Health." Korean Journal of Family Practice. Vol. 10, No. 2, pp.87-95. April 2020 DOI: 10.21215/kjfp.2020.10.2.87
  10. A. Saglietto, F. D'Ascenzo, G. B. Zoccai and G. M. FerrarH. "COVID-19 in Europe: the Italian lesson". Lancet, Vol. 395, No. 10230, pp. 1110-1111. Arpil 2020 DOI: 10.1016/S0140-6736(20)30690-5.
  11. W. Ji, K. Huh, M. Kang, J. Hong, G. H. Bae, R. Lee, Y. Na, H. Choi, S. Y. Gong, Y. H. Choi, K. P. Ko, J. S. Im and J. Jung. "Effect of Underlying Comorbidities on the Infection and Severity of COVID-19 in Korea: A Nationwide Case-Control Study". Journal of Korean Medication Science. Vol. 35, No. 25, pp.e237. Jun 2020 DOI: 10.3346/jkms.2020.35.e237
  12. N. Chen, M. Zhou, X. Dong, J. Qu. F. Gong, Y. Han and L. Zhang. "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study". Lancet Vol. 395, No. 10223, pp.507-13. Feb. 2020 DOI: 10.1016/S0140-6736(20)30211-7
  13. W. J. Guan, Z.Y. Ni, Y. Hu, W. H. Liang, C. Q. Ou and J. X. He. "Clinical characteristics of coronavirus disease 2019 in China" New England journal of medicine, Vol. 58, No. 3, pp.711-712. April 2020 Doi: 10.1056/NEJMoa2002032.
  14. D. Wang, B. Hu, C. Hu, F. Zhu, X. Liu and J. Zhang. "Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China". JAMA, Vol. 323, No. 11, pp.1061-1069. Feb. 2020 Doi: 10.1001/jama.2020.1585.
  15. Chinese Center for Disease Control and Prevention. Epidemic update and risk assessment of 2019 novel coronavirus [Internet]. Beijing: Chinese Center for Disease Control and Prevention; 2020 [cited 2020 Apr 14]. Available: http://www.chinacdc.cn/yyrdgz/202001/P020200128523354919292.pdf.
  16. G. M. Kuster, O. Pfister, T. Burkard, Q. Zhou, R. Twerenbold and P. Haaf. "SARSCoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?" European Heart Journal, Vol. 41, No. 19, pp. ehaa235. March 2020 Doi: 10.1093/eurheartj/ehaa235.
  17. S. R. Weiss, S. Navas-Martin. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev. Vol. 69, No. 4. December 2005 pp. 635 - 664. https://doi.org/10.1128/MMBR.69.4.635-664.2005.
  18. N. R. Sexton, E. Smith, H. Blanc, M. Vignuzzi, O. Peersen, M. R. Denison. Homology-based identification of a mutation in the coronavirus RNA dependent RNA polymerase that confers resistance to multiple mutagens. J Virol. Vol. 90, No. 16, pp. 7415-7428. Auguest 2016 https://doi.org/10.1128/JVI.00080-16